Peptide Profile
Tabimorelin
An investigational oral growth hormone secretagogue that stimulates GH release through ghrelin receptor activation, though development was discontinued due to drug interaction concerns.
Dose Range
100-500mg
Frequency
Once daily
Route
Oral (capsule or solution)
Cycle Length
4-6 weeks
Onset
Moderate (1-2 weeks)
Evidence
Moderate
Compound Profile
Scientific & Efficacy Data
C32H40N4O3
Molecular Formula
528.7 g/mol
Molecular Weight
Several hours (exact human half-life not published; dose-dependent pharmacokinetics)
Half-Life
Orally active with dose-dependent bioavailability (increases at higher doses)
Bioavailability
193079-69-5
CAS #
9810101
PubChem ID ↗
Developed By · 1999
Novo Nordisk Research Team
Novo Nordisk A/S
Primary Benefits
Potent, dose-dependent GH elevation starting at 1.5 mg/kg; significant IGF-1 increases at higher doses, supporting anabolism and GH-mediated benefits
Non-injection, oral formulation enhances user compliance and avoids injection-site reactions; suitable for extended-use protocols
Does not significantly elevate prolactin, cortisol, or ACTH at most doses; however, CYP3A4 inhibition and rapid tolerance development limit overall safety and efficacy profile
Amino Acid Sequence
N/A — Non-peptide small molecule (peptidomimetic growth hormone secretagogue)Dosing
How much
do I take?
Timing
Best time to take
Evening or before bedtime (mirrors natural GH secretion patterns)
With food?
Take Tabimorelin on an empty stomach for optimal absorption, or with a light meal if GI discomfort occurs. Avoid heavy meals within 30 minutes of dosing.
If stacking
If combining Tabimorelin with other peptides or supplements, space administrations by at least 15-30 minutes when possible. Consult with a healthcare provider before combining with prescription medications.
Adjusting Your Dose
Increase if
- +You've tolerated the current dose for the recommended period without significant side effects
- +Therapeutic goals haven't been met at the current dose level
- +Your healthcare provider recommends dose escalation based on your response
- +Lab work or clinical assessments support a higher dose
Decrease if
- -Side effects are bothersome or impacting daily life despite management strategies
- -You experience any signs of an adverse reaction
- -Lab results indicate the need for dose reduction
- -Your healthcare provider recommends a lower dose based on your response
Signs of right dose
- ✓Therapeutic goals being met with minimal side effects
- ✓Stable and consistent response to treatment
- ✓Lab values or clinical markers trending in the right direction
- ✓Good tolerance with manageable or absent side effects
Dosing Calculator
Calculate Your Exact Dose
Step 1: Peptide Weight
Find the weight printed on your peptide vial label
Look here!
The peptide weight is printed on the label
Look here!
The weight is on the label
Suitability
Is this
right for me?
Who Should Avoid
Do not use if
- ×Active or history of carcinomas (ghrelin receptor agonists may stimulate growth of certain tumors)
- ×Concurrent use of potent CYP3A4 substrates due to risk of dangerous drug-drug interactions
- ×Untreated thyroid dysfunction
- ×Uncontrolled diabetes
Use with caution if
- !You are taking other medications—discuss potential interactions with your healthcare provider
- !You have a history of liver or kidney disease
- !You are elderly or have multiple medical conditions
- !You are planning surgery in the near future—inform your surgeon about Tabimorelin use
- !You have any chronic health conditions that require regular monitoring
Administration
How do I
use it?
Reconstitution
What you need
- •Tabimorelin in its prescribed form
- •Clean, dry storage container
- •Measuring device if applicable (oral syringe, measuring cup)
- •Calendar or reminder app for dosing schedule
Injection
Route
Not applicable — oral formulation only
Best sites
- •N/A — oral administration only, not administered by injection
Technique
- 1.Tabimorelin is taken orally in capsule or solution form, not via injection
- 2.Take with or without food as directed
- 3.Swallow capsules whole with water
- 4.Follow exact dosing instructions on prescription label
Storage
Signs of degradation
Safety
Is it
safe?
Safety Profile
Tabimorelin is an oral GHS-R agonist with preclinical and early clinical data indicating dose-dependent appetite stimulation (potentially problematic for weight-conscious users) and transient blood glucose elevation due to GH's insulin-antagonistic effects. No human safety database exists beyond Phase 1/2 studies—efficacy and long-term safety profile in humans remain incompletely characterized. Potential risks include carpal tunnel syndrome (documented with chronic GH therapy), arthralgias, and theoretical tumor growth acceleration, though these are extrapolated from GH physiology rather than directly observed in limited human exposure.
Safety information is limited to rat and limited human Phase 1/2 data; no Phase 3 efficacy trials have been completed. GH secretagogue class effects (appetite stimulation, glucose dysregulation) are expected based on mechanism, but individual tolerability variability is substantial. Long-term human safety data beyond 12 weeks does not exist—any use should be considered experimental with careful clinical monitoring including fasting glucose and IGF-1 levels.
Common Side Effects
Experienced by some users
Headache
Mild to moderate headache onset within 1-2 hours of dosing, typically frontal or temporal. Reported in ~30% of users in early clinical trials. Usually improves with repeated dosing as body tolerates ghrelin stimulation.
Management: Take with food to slow absorption and reduce intensity. Ibuprofen or acetaminophen (500 mg) effective if needed. Stay well-hydrated—dehydration worsens headaches. Divide dose (AM + PM instead of single dose) if tolerated. Most headaches diminish by day 3-5 with continued use.
Nausea
Mild to moderate nausea onset within 30 minutes to 2 hours post-dose. Reflects ghrelin receptor stimulation in the chemoreceptor trigger zone. Reported in ~20-25% of users. Usually mild and self-limited but can be distressing.
Management: Take immediately after eating (not on empty stomach) to buffer gastric irritation. Ginger (500 mg capsule or tea) is highly effective and natural. Ondansetron (4-8 mg) or metoclopramide (10 mg) work if ginger insufficient. Ensure adequate hydration. Most users report nausea resolves by day 3-5 as chemoreceptor tolerance develops.
Appetite stimulation
Ghrelin mimicry causes progressive appetite increase starting day 2-3. Peak hunger typically days 7-14. Mediated via NPY/AgRP pathways in lateral hypothalamus. Expected and intended effect reflecting proper ghrelin receptor activation.
Management: If weight gain is undesired, portion control at meals is essential—use smaller plates and eat slowly. Increase protein proportion to promote satiety. Avoid keep snacks available in visible locations. Time dosing away from peak hunger (early morning on empty stomach, not pre-meal). Increase aerobic activity to offset caloric surplus. This effect usually stabilizes by week 3-4.
Dizziness
Mild to moderate lightheadedness or vertigo onset within 30-90 minutes post-dose. Likely reflects acute cardiovascular changes from GH stimulation and ghrelin receptor activation. Usually mild and transient.
Management: Avoid driving or operating heavy machinery for 1-2 hours after dosing. Sit or lie down if dizziness occurs. Stay well-hydrated. Slow positional changes—rise from sitting slowly. Blood pressure monitoring may reveal mild changes. Dizziness usually diminishes by day 2-3 as tolerance develops.
Dry mouth
Xerostomia develops gradually within 1-4 hours post-dose. Results from ghrelin receptor stimulation affecting salivary gland function and increased metabolic rate. Usually mild but can be bothersome.
Management: Increase overall fluid intake to 2.5-3 liters daily. Sip water frequently throughout day. Sugar-free gum/lozenges stimulate saliva production. Avoid caffeinated beverages (worsen dehydration). Mouth rinse with water before bed. Most cases resolve by day 3-7 with consistent hydration.
Stop and Seek Help If
- ×Severe or worsening side effects that don't improve with dose adjustment or supportive care
- ×Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- ×Your healthcare provider recommends discontinuation based on your clinical response
- ×Development of any new medical condition that may be contraindicated with Tabimorelin
- ×Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- ×Abnormal lab results or clinical markers that suggest adverse effects
Tabimorelin should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Interactions
With other peptides
- ✓May be used together under medical guidance.
- ✓May be used together under medical guidance.
- ✓May be used together under medical guidance.
With medications
- !Strong CYP3A4 inhibitors (itraconazole, ritonavir, clarithromycin) — tabimorelin itself inhibits CYP3A4, creating bidirectional interaction risks - Use with caution—discuss with your healthcare provider.
- !CYP3A4 substrates (statins, certain antiarrhythmics, immunosuppressants) without careful monitoring - Use with caution—discuss with your healthcare provider.
With supplements
- ✓Multivitamins - Generally safe to take alongside Tabimorelin. Space doses apart if taking oral formulations to ensure optimal absorption.
- ✓Electrolyte supplements - Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Effectiveness
Does it
work?
Evidence Level
Moderate human trials
What to Expect
First dose
What you might notice
- •GH elevation occurs within 30–60 minutes;
- •peak typically at 60–90 minutes post-dose
What's normal
- •Full integration of Tabimorelin into physiological systems is established
- •Long-term Tabimorelin response remains personalized to your physiology
- •Tabimorelin tolerance is well-maintained with consistent dosing
What's next
- →Maintain your established Tabimorelin protocol for sustained benefits
- →Continue periodic monitoring to confirm Tabimorelin efficacy
- →Review comprehensive Tabimorelin response with your provider
Days 1–3
What you might notice
- •Mild headache, nausea, or dizziness may emerge;
- •appetite begins to increase
What's normal
- •Tabimorelin is achieving sufficient receptor engagement
- •Initial mechanism of Tabimorelin is taking effect
- •Early transient effects from Tabimorelin administration are resolving
What's next
- →Maintain consistent Tabimorelin administration as prescribed
- →Document subjective effects and physical markers daily
- →Schedule a check-in with your provider about initial observations
Days 4–7
What you might notice
- •Continued GH elevation on each dose;
- •tolerance may begin to develop in some individuals (seen clinically as reduced GH peak)
What's normal
- •Tabimorelin is achieving sufficient receptor engagement
- •Initial mechanism of Tabimorelin is taking effect
- •Early transient effects from Tabimorelin administration are resolving
What's next
- →Maintain consistent Tabimorelin administration as prescribed
- →Document subjective effects and physical markers daily
- →Schedule a check-in with your provider about initial observations
Weeks 2–4
What you might notice
- •Sustained appetite stimulation;
- •modest gains in muscle or lean mass possible with adequate protein and training;
- •GH response plateaus or declines in some users
What's normal
- •Tabimorelin is now achieving steady-state pharmacokinetics
- •Measurable changes aligned with Tabimorelin's mechanism may appear
- •Initial adjustment effects typically resolve by this point
What's next
- →Maintain Tabimorelin dosing exactly as established
- →Track progress toward intended outcomes in detail
- →Review lab work or biomarker changes with your healthcare team
Weeks 4–6
What you might notice
- •End of typical cycle;
- •benefits plateau or decline as tolerance fully develops;
- •discontinuation recommended per protocol
What's normal
- •Tabimorelin is now achieving steady-state pharmacokinetics
- •Measurable changes aligned with Tabimorelin's mechanism may appear
- •Initial adjustment effects typically resolve by this point
What's next
- →Maintain Tabimorelin dosing exactly as established
- →Track progress toward intended outcomes in detail
- →Review lab work or biomarker changes with your healthcare team
Days after discontinuation
What you might notice
- •GH levels return to baseline within 24–48 hours;
- •appetite normalizes;
- •no rebound adverse effects
What's normal
- •Tabimorelin response patterns are emerging
- •Initial Tabimorelin response is consistent with mechanism expectations
- •Early tolerance development to Tabimorelin is not expected
What's next
- →Assess whether Tabimorelin response aligns with expectations
- →Plan next steps based on initial Tabimorelin tolerance and response
- →Establish baseline monitoring for Tabimorelin response tracking
Not Seeing Results?
Common reasons
- •Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
- •Insufficient time at target dose—most compounds need several weeks to show full benefits
- •Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
- •Individual variation in response—genetics, metabolism, and other factors affect outcomes
- •Underlying conditions or medications interfering with absorption or effectiveness
- •Improper storage leading to degraded product—always verify proper storage conditions
Key Research
"The pharmacokinetics, pharmacodynamics, safety and tolerability of a single dose of NN703, a novel orally active growth hormone secretagogue in healthy male volunteers"
Zdravkovic M, et al., 2000
Finding: This study investigated the properties and effects of Tabimorelin, contributing to our understanding of its mechanism of action and potential therapeutic applications.
View Study"Oral administration of NN703 in adult patients with growth hormone deficiency"
Svensson J, et al., 2003
Finding: This study investigated the properties and effects of Tabimorelin, contributing to our understanding of its mechanism of action and potential therapeutic applications.
View Study"Pharmacokinetic and pharmacodynamic modeling of NN703 after a single oral dose to human volunteers"
Agersø H, et al., 2001
Finding: This study investigated the properties and effects of Tabimorelin, contributing to our understanding of its mechanism of action and potential therapeutic applications.
View StudyFrequently Asked Questions